Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Rachel Lubong Sabado, Anna C. Pavlick, Sacha Gnjatic, Crystal M Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie Holman, Juliet Escalon, Caroline Muren, Crystal Escano, Ethel Yepes, Dunbar Sharpe, Sylvia Adams, Patrick Alexander Ott, Achim A Jungbluth, Linda S. Pan, Ralph Rudolph Venhaus, Nina Bhardwaj
Institutions: New York University, Ludwig Cancer Research, NYU Langone Health
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2908355979